MedPath

Fluconazole

Generic Name
Fluconazole
Brand Names
Diflucan
Drug Type
Small Molecule
Chemical Formula
C13H12F2N6O
CAS Number
86386-73-4
Unique Ingredient Identifier
8VZV102JFY
Background

Fluconazole, commonly known as Diflucan, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an azole antifungal, in the same drug family as ketoconazole and itraconazole. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.

Indication

Fluconazole can be administered in the treatment of the following fungal infections:

1) Vaginal yeast infections caused by Candida

2) Systemic Candida infections

3) Both esophageal and oropharyngeal candidiasis

4) Cryptococcal meningitis

5) UTI (urinary tract infection) by Candida

6) Peritonitis (inflammation of the peritoneum) caused by Candida

A note on fungal infection prophylaxis

Patients receiving bone marrow transplantation who are treated with cytotoxic chemotherapy and/or radiation therapy may be predisposed to candida infections, and may receive fluconazole as prophylactic therapy.

A note on laboratory testing

Obtaining specimens for fungal culture and other important laboratory studies such as serology or pathology is advised before starting fluconazole therapy in order to isolate the organisms to be eliminated through treatment. It is permissible to start therapy before the results are available, however, adjusting the therapy once laboratory results confirm the causative organism may be necessary.

Associated Conditions
Candida intertrigo, Candida pneumonia, Candida urinary tract infection, Candidemia, Candidiasis, Coccidioidomycosis, Esophageal Candidiasis, Fungal Infections, Fungal peritonitis caused by Candida, Meningitis, Cryptococcal, Oropharyngeal Candidiasis, Peritoneal candidiasis, Pneumonia cryptococcal, Pruritus, Skin Irritation, Systemic Candida Infections caused by Candida, Vaginal Candidiasis, Disseminated Candidiasis

Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis

Phase 4
Completed
Conditions
Candidiasis, Vulvovaginal
Interventions
First Posted Date
2014-07-03
Last Posted Date
2017-05-02
Lead Sponsor
Peking University Shenzhen Hospital
Target Recruit Count
240
Registration Number
NCT02180828
Locations
🇨🇳

Peking University Shenzhen Hospital, Shenzhen, Guangdong, China

Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis

Phase 4
Completed
Conditions
Vulvovaginal Candidiasis
Interventions
First Posted Date
2014-07-02
Last Posted Date
2020-10-23
Lead Sponsor
Peking University Shenzhen Hospital
Target Recruit Count
140
Registration Number
NCT02180100
Locations
🇨🇳

Peking University Shenzhen Hosptal, Shenzhen, Guangdong, China

Fluconazole Versus Micafungin in Neonates with Candidiasis

Phase 2
Completed
Conditions
Candidiasis
Interventions
First Posted Date
2014-05-23
Last Posted Date
2025-01-29
Lead Sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Target Recruit Count
100
Registration Number
NCT02145832

Effects of Fluconazole and Itraconazole CYP3A-Mediated Inhibition on the Pharmacokinetics, Safety, and Tolerability of MLN4924 in Participants With Advanced Solid Tumors

First Posted Date
2014-04-25
Last Posted Date
2019-01-07
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Target Recruit Count
51
Registration Number
NCT02122770
Locations
🇺🇸

Sarah Cannon Cancer Center, Nashville, Tennessee, United States

🇺🇸

Winship Cancer Institute at Emory University, Atlanta, Georgia, United States

🇺🇸

Siteman Cancer Center - South County, Saint Louis, Missouri, United States

and more 1 locations

Safety and Clinical and Microbiological Efficacy of the Combination of Fluconazole and Secnidazole for the Treatment of Symptomatic Vaginal Discharge

Phase 3
Completed
Conditions
Vaginal Discharge
Interventions
First Posted Date
2014-04-11
Last Posted Date
2014-04-11
Lead Sponsor
Universidad Nacional de Colombia
Target Recruit Count
118
Registration Number
NCT02111629
Locations
🇨🇴

Hospital de Engativá, Bogotá D.C, Colombia

A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects

Phase 1
Completed
Conditions
Prostate Cancer
Endometriosis
Interventions
First Posted Date
2014-03-21
Last Posted Date
2016-06-06
Lead Sponsor
Millennium Pharmaceuticals, Inc.
Target Recruit Count
40
Registration Number
NCT02093390

To Assess the Effect of Itraconazole and Fluconazole on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers

Phase 1
Completed
Conditions
Solid Tumours
Interventions
First Posted Date
2014-03-21
Last Posted Date
2015-06-30
Lead Sponsor
AstraZeneca
Target Recruit Count
26
Registration Number
NCT02093728
Locations
🇺🇸

Research Site, Overland Park, Kansas, United States

Micafungin Versus Fluconazole for Prevention of Invasive Fungal Disease in Living Donor Liver Transplant Recipients

Phase 3
Conditions
Liver Transplant Recipient
Interventions
First Posted Date
2013-11-01
Last Posted Date
2013-11-01
Lead Sponsor
Asan Medical Center
Target Recruit Count
172
Registration Number
NCT01974375
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

High Dose Fluconazole in Cutaneous Leishmaniasis in Bahia and Manaus

Phase 3
Terminated
Conditions
Cutaneous Leishmaniasis
Interventions
First Posted Date
2013-10-01
Last Posted Date
2015-12-02
Lead Sponsor
Hospital Universitário Professor Edgard Santos
Target Recruit Count
53
Registration Number
NCT01953744
Locations
🇧🇷

Posto de Saúde de Corte de Pedra, Presidente Tancredo Neves, Bahia, Brazil

Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease

Phase 1
Terminated
Conditions
Graft vs Host Disease
Stem Cell Transplantation
Interventions
First Posted Date
2013-09-25
Last Posted Date
2021-03-12
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Target Recruit Count
15
Registration Number
NCT01950507
Locations
🇺🇸

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath